TISSARA Trial: Ticagrelor Intervention to Reduce Stent Thrombosis and Acute MI Risk
NCT ID: NCT06667349
Last Updated: 2024-10-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
1727 participants
INTERVENTIONAL
2023-08-24
2024-06-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The TISSARA Trial is designed to rigorously assess the effectiveness of this intervention on cardiovascular outcomes in STEMI patients.
Between August, 2023 and March 2024, a total of 1,773 patients were enrolled in the trial, with 970 patients discharged on Tissara (Ticagrelor) (Ferozsons laboratories Ltd, Lahore, Pakistan) (TG) and 803 patients receiving clopidogrel (CG) following their primary PCI procedures. Each group was carefully monitored for a duration of three months to evaluate the incidence of stent thrombosis and other relevant cardiovascular events. The primary endpoint of this trial is the occurrence of stent thrombosis within the follow-up period, providing critical insights into the safety and efficacy of the ticagrelor regimen in this high-risk population.
This comprehensive approach aims to contribute valuable data that may influence future treatment protocols and improve the standard of care for patients undergoing PCI in similar healthcare settings.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study Cohorts:
* Ticagrelor Cohort: Comprises consecutive patients receiving ticagrelor as part of the dual antiplatelet therapy (DAPT) regimen mandated for a minimum of two weeks post PPCI.
* Clopidogrel Cohort: Included patients who received clopidogrel as part of the conventional DAPT protocol.
Selection Criteria:
• All consecutive patients presenting with ST-elevation myocardial infarction (STEMI) and undergoing primary PCI with drug-eluting stents (DES).
Exclusion Criteria:
* Patients who underwent plain old balloon angioplasty (POBA) or left heart catheterization (LHC) only.
* Patients who declined to provide consent.
* Patient with high bleeding risk
* Prior history of IC hemorrhage
* Prior CVA within past one year
* On oral anticoagulant Study Variables and Operational Definitions
* ST-Elevation Myocardial Infarction (STEMI): Diagnosis based on at least two of the following criteria:
* Typical chest pain lasting more than 20 minutes, characterized by retrosternal pain radiating to the left arm or shoulder, worsening with exertion or emotional stress, and alleviated by rest or nitroglycerin.
* New ST elevation in at least two contiguous leads: greater than 2 mm in men or greater than 1 mm in women in leads V2 to V3, and/or greater than 1 mm in other contiguous chest leads or limb leads.
* Primary PCI: The strategy of directly taking a STEMI patient to the cardiac catheterization laboratory for mechanical revascularization via balloon angioplasty and coronary stenting.
* Stent Thrombosis:
* Definite Stent Thrombosis: Confirmed by angiographic or pathological evidence of partial or total thrombotic occlusion within the peri-stent area, along with acute ischemic symptoms, ischemic ECG changes, or elevated cardiac biomarkers.
* Probable Stent Thrombosis: Unexplained death within 30 days of stent implantation or myocardial infarction related to documented acute ischemia in the stented territory, without angiographic confirmation of stent thrombosis.
* Possible Stent Thrombosis: Unexplained death occurring beyond 30 days.
* Early Stent Thrombosis: Occurs within 24 hours post-PCI.
* Subacute Stent Thrombosis: Occurs from 24 hours to 30 days post-PCI.
* Major Adverse Cardiovascular Events (MACE): Defined as a composite of:
* All-cause mortality
* Cardiovascular mortality
* Myocardial infarction (with or without revascularization)
* Unplanned hospitalization due to heart failure
* Stroke or cerebrovascular events Data Collection Procedure The study was conducted after receiving approval from the ethical review committee of NICVD, Karachi. Verbal informed consent was obtained from all participants, ensuring confidentiality. Patients presenting with STEMI who underwent primary PCI with second-generation DES were included. Data on demographic characteristics, financial status, treatment compliance, complications, hospitalizations, and emergency room visits were collected using a structured questionnaire. The collected data were securely stored and accessible to the primary investigators and co-investigators. Patients were followed up at 15 days and one month in the outpatient clinic to assess medication compliance, side effects, and bleeding.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tiacgrelor (Tissara) 90 mg pod BID
Ticagrelor 90 mg bid give for atleast two weeks and ideally upto a month
Ticagrelor
Ticagrelor 90 mg PO BID given for atleast two weeks following primary PCI
standard arm clopidogrel 75 mg qday
Ticagrelor
Ticagrelor 90 mg PO BID given for atleast two weeks following primary PCI
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ticagrelor
Ticagrelor 90 mg PO BID given for atleast two weeks following primary PCI
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients who declined to provide consent.
* Patient with high bleeding risk
* Prior history of IC hemorrhage
* Prior CVA within past one year
* On oral anticoagulant
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Cardiovascular Diseases, Pakistan
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Professor Abdul Hakeem
Professor Abdul Hakeem MD FACC FSCAI FASE
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Abdul Hakeem, MD
Role: PRINCIPAL_INVESTIGATOR
National Institute of Cardiovascular Diseases
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institute of Cardiovascular Diseases
Karachi, Sindh, Pakistan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kumar R, Ammar A, Saghir T, Sial JA, Shah JA, Kumar A, Shaikh AH, Achakzai AS, Qamar N, Karim M. Incidence, Predictors, and Outcomes of Acute and Sub-acute Stent Thrombosis after Emergency Percutaneous Coronary Revascularization with Drug-Eluting Stents: A Prospective Observational Study. Glob Heart. 2022 Mar 30;17(1):24. doi: 10.5334/gh.1112. eCollection 2022.
Schulz S, Schuster T, Mehilli J, Byrne RA, Ellert J, Massberg S, Goedel J, Bruskina O, Ulm K, Schomig A, Kastrati A. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. Eur Heart J. 2009 Nov;30(22):2714-21. doi: 10.1093/eurheartj/ehp275. Epub 2009 Jul 11.
Dubey G, Verma SK, Bahl VK. Primary percutaneous coronary intervention for acute ST elevation myocardial infarction: Outcomes and determinants of outcomes: A tertiary care center study from North India. Indian Heart J. 2017 May-Jun;69(3):294-298. doi: 10.1016/j.ihj.2016.11.322. Epub 2016 Nov 30.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NICVD IRB-40/2023
Identifier Type: -
Identifier Source: org_study_id